Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Atriva Therapeutics.

    Client Virtual Booth

    ATRIVA THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Atriva Therapeutics
    Germany Flag
    Country
    Country
    Germany
    Address
    Address
    Christophstrasse 32, 72072 Tuebingen
    Telephone
    Telephone
    +49 (0) 7071 8597673
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.atriva-therapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/atriva-therapeutics-gmbh/
    Twitter
    Twitter
    https://twitter.com/AtrivaTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology

    Details:

    Through the acquisition, Atriva aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA-viruses, including ATR-002 (zapnometinib), a first-in-class, host-targeting agent that aims to inhibit viral replication.


    Lead Product(s): zapnometinib

    Therapeutic Area: Infections and Infectious Diseases Product Name: ATR-002

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Biocure Technology

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition September 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19

    Details:

    RESPIRE1 is an international, multi-center Phase II clinical trial in 220 adult patients with moderate to severe COVID-19, requiring hospitalization, but not requiring ICU admission or ventilator support at the time of screening or randomization.


    Lead Product(s): zapnometinib

    Therapeutic Area: Infections and Infectious Diseases Product Name: ATR-002

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 13, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Publication in PNAS Unveils Molecular Pathway Required for Influenza Virus Replication with Large Potential as an Antiviral Drug Target

    Details:

    ATR-002 is an oral small molecule, in a dose escalation study demonstrated excellent safety and tolerability and the observed pharmacokinetic profile supports the intended once-daily regime for the upcoming Phase II clinical development.


    Lead Product(s): zapnometinib

    Therapeutic Area: Infections and Infectious Diseases Product Name: ATR-002

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 30, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study

    Details:

    Atriva’s lead product ATR-002 candidate is the only host-targeted antiviral specifically developed to treat respiratory infections with RNA viruses, such as influenza virus and the novel SARS-CoV-2.


    Lead Product(s): zapnometinib

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 28, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search